
    
      Studies have shown that a favorable microbiome can be the difference between response and
      non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the
      investigators propose to ensure a favorable microbiome in this patient by fecal microbiota
      transplant to enhance the efficacy of such a drug, Keytruda.
    
  